Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Oct. 28 Quick Takes: Gilead returns to $100B market cap on strong earnings

Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more

October 28, 2022 11:57 PM UTC

Shares of Gilead Sciences Inc. (NASDAQ:GILD) rose $9.07 (13%) to $79.27 to bring the company’s market cap to nearly $100 billion after the company handily beat 3Q consensus estimates for EPS and revenue and raised its 2022 guidance. The company reported non-GAAP EPS of $1.90, compared with the Street’s $1.43, on revenues of $7 billion, which beat the consensus of $6.1 billion. Sales of the biotech’s cell therapies increased 79% to $398 million, and sales of Biktarvy bictegravir/emtricitabine/tenofovir alafenamide rose 22% to $2.8 billion. The company is now expecting non-GAAP EPS of $6.95-$7.15, up from $6.35-$6.75, and product sales $25.9-$26.2 billion vs prior guidance $24.5-$25 billion. The company also announced the receipt of a complete response letter for a BLA for bulevirtide to treat adults with hepatitis delta virus infection and compensated liver disease; it gained the therapy through its 2021 acquisition of MYR GmbH for nearly €1.2 billion ($1.17 billion).

Vaccines were the highlight of the third quarter earnings for Sanofi (Euronext:SAN; NASDAQ:SNY), with sales driven by strong influenza revenues and travel vaccinations leading to an increase of 23.5% over the same quarter last year. Sanofi reported €12.5 billion in net sales for the third quarter and €32.3 billion for the first nine months of 2022. The pharma also recorded an impairment of €1.7 billion for the quarter, €1.6 million of which was related to SAR444245, the company’s non-alpha IL-2 gained through the acquisition of Synthorx Inc. The IL-2 field has faced several setbacks over the last year, including the Phase III miss of bempegaldesleukin that led to the reorganization of Nektar Therapeutics (NASDAQ:NKTR)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article